Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice

Novo Nordisk A/S1,935 enrolled

Overview

This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard® 30 NovoLet® used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2 diabetes mellitus in an out-patient setting.

Study Type

OBSERVATIONAL

Enrollment

1,935

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic human insulin 30DRUG

Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Not adequately controlled on their current therapy

Locations (1)

Novo Nordisk Investigational Site

Jakarta, Indonesia

Outcomes

Primary Outcomes

Change in fasting blood glucose (FBG)

Change in 2-hour post prandial blood glucose

Change in HbA1c (glycosylated haemoglobin)

Change in prandial glucose increment (PGI)

Secondary Outcomes

Frequency of minor and major hypoglycaemia

Occurrence of Adverse Drug Reactions (ADR)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.